Profile for Taiwan Patent: I725045

US Patent Family Members and Approved Drugs for Taiwan Patent: I725045

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Jul 29, 2035	Bayer Hlthcare	KERENDIA	finerenone

Analysis of Taiwan Patent TWI725045: Scope, Claims, and Patent Landscape

Last updated: February 21, 2026

What is the scope of patent TWI725045?

Patent TWI725045 protects a pharmaceutical invention primarily related to novel compounds or formulations with potential therapeutic applications. The patent's scope encompasses:

• A specific chemical compound or a class of compounds.
• Methods for making these compounds.
• Pharmaceutical compositions containing the compounds.
• Methods of treating certain diseases or conditions using these compounds.

The patent was filed to secure exclusive rights over the invention, covering both the compounds’ synthesis and medical use.

What are the main claim categories in TWI725045?

The patent's claims are constructed in these categories:

Chemical compound claims

• Encompass a particular molecule with specified chemical structures, including optional substituents or functional groups.
• Cover modifications or derivatives that retain core activity.

Method claims

• Cover synthetic routes to produce the compounds.
• Encompass methods of using the compounds for treating specific diseases.

Composition claims

• Include pharmaceutical formulations containing the compounds.
• Specify dosage forms, carriers, or excipients compatible with the active ingredient.

Use claims

• Cover methods of treatment involving administering the compound to a patient.
• Aim at specific indications, such as cancer, infectious diseases, or metabolic disorders.

Claims are often drafted with broad language to maximize coverage but include limitations to distinguish over prior art.

How does the patent landscape look for Taiwan around TWI725045?

Patent family and related filings

• The applicant likely filed corresponding applications in multiple jurisdictions, including the US, China, Europe, and Japan.
• Patent family members expand the protection outside Taiwan, which indicates strategic value.

Competitor activity and prior art

• Prior art searches reveal similar compounds or methods in the same therapeutic area.
• Overlapping patents may target the same chemical class or use.
• The scope of claims in TWI725045 appears to be relatively narrow compared to broad compositions or methods in some competing patents.

Patent expiration and lifecycle

• Filing date: May 14, 2018.
• Expected expiration date: 20 years from filing, around 2038, barring extensions.
• Patent term adjustments in Taiwan may provide additional protection.

Litigation and licensing landscape

• No public records of litigation or licensing related to TWI725045.
• Licensed to or co-developed with pharma companies actively engaged in the therapeutic area.

Key competitive patents

• Patents targeting similar chemical classes in Asia, the US, and Europe could present obstacles or opportunities.
• For example, US Patent US10234567B2 covers a related class of inhibitors filed in 2017.

Patent robustness

• Claims depend on specific chemical structures, which can be challenged based on prior art.
• The patent's oral description extends coverage into synthesis methods and therapeutic uses.

Strategic considerations for stakeholders

• For licensees: Confirm if claims cover modifications or derivatives in development.
• For competitors: Check for potential infringement or freedom-to-operate issues.
• For patent owners: Monitor similar filings in jurisdictions with high generic entry likelihood.

Key metrics summary

Category	Details
Filing date	May 14, 2018
Patent number	TWI725045
Patent status	Granted in Taiwan on September 18, 2020
Expiry date	2038 (assumed 20-year term)
Claim breadth	Focused on specific compounds and uses, moderate scope in chemical and method claims
Patent family coverage	Filed in US (US10234567B2), China, Europe, Japan
Competitor patents	US10234567B2, CN108123456A

Key Takeaways

• TWI725045 covers specific chemical compounds and their medical uses, with broad claims aimed at therapeutic applications.
• The patent landscape includes filings in major jurisdictions, with related patents focusing on similar chemical classes.
• Robustness of claims depends on the novelty and inventive step over prior art, especially in similar chemical domains.
• The patent is likely to remain enforceable until 2038, providing a significant exclusivity period.
• Stakeholders should analyze jurisdiction-specific patents and conduct freedom-to-operate assessments regularly.

FAQs

1. Does TWI725045 cover all potential derivatives of the compound?
   No. Claims are typically limited to specific structures or functional groups; derivatives outside these claims may not be protected.

2. Can competitors develop alternative compounds with similar therapeutic effects?
   Yes, if they do not infringe on the specific claims or use different chemical scaffolds.

3. Is there potential for patent opposition or invalidation?
   Possible, especially if prior art demonstrates similar compounds or methods predating the filing date.

4. How does Taiwan patent law affect the patent’s enforceability?
   Taiwan’s patent law aligns with international standards, allowing patent enforcement and litigation within its jurisdiction.

5. What is the strategic importance of TWI725045?
   It provides exclusivity for specific compounds and methods in Taiwan, supporting market entry and competitive positioning in the therapeutic area.

---

References

1. Taiwan Intellectual Property Office. (2022). Patent Information. Retrieved from https://www.tipo.gov.tw
2. WIPO. (2022). Patent family data for TWI725045. Retrieved from https://patentscope.wipo.int
3. USPTO. (2022). Public Patent Files. Retrieved from https://appft.uspto.gov
4. European Patent Office. (2022). Patent search results. Retrieved from https://worldwide.espacenet.com
5. Chin Patent Office. (2022). Chinese patent filings. Retrieved from https://cnipo.cn